ArticleCancer immunology, immunotherapy : CII2025
Exploring IgSF11 as a potential immune checkpoint and immunotherapeutic target in breast cancer.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The immunoglobulin superfamily 11 (IgSF11) represents a novel immune checkpoint ligand, increasingly recognized as a promising candidate for cancer immunotherapy. In this study, we investigated the clinicopathological significance of IgSF11 expression and its correlation with inhibitory immune checkpoints, including programmed cell death 1 (PD-1), its ligand PD-L1, cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), as well as V-domain Ig suppressor of T cell activation (VISTA), within the tumor microenvironment of breast cancer patients. Two complementary approaches were employed, encompassing transcriptomic analysis using large-scale datasets, namely the Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohorts, as well as a proteomic analysis conducted via immunohistochemistry (IHC) in a Moroccan cohort. Our transcriptomic findings suggest that IgSF11 mRNA expression is associated with aggressive clinicopathological features, particularly the basal-like breast cancer molecular subtype, and shows a positive correlation with inhibitory immune checkpoints, most notably its receptor VISTA. Additionally, gene set enrichment analysis (GSEA) demonstrated a significant association between a high IgSF11 expression and key tumor-promoting pathways, including epithelial-mesenchymal transition, angiogenesis, hypoxia, and immunosuppression. IHC analysis further revealed that IgSF11 staining was significantly upregulated in breast tumor tissues compared to adjacent uninvaded control tissues. Unexpectedly, IgSF11 protein was uniformly positive across all breast cancer molecular subtypes, and exhibited a trend toward a negative correlation with VISTA. Taken together, our data suggest that IgSF11 expression may play a central role in breast cancer pathogenesis and immune evasion supporting the potential of IgSF11 blockade as a promising immunotherapeutic strategy for breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.